2-(5-溴-2-噻酚)吡啶 | 123784-07-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-(5-溴-2-噻酚)吡啶
• 中文别名: 2-(5-溴-2-噻吩基)吡啶
• 英文名称: 2-(5-bromothiophen-2-yl)pyridine
• 英文别名: 2-(5-bromo-2-thienyl)pyridine；2-bromo-5-(2'-pyridyl)thiophene；2-bromo-5-(pyrid-2-yl)thiophene
• CAS: 123784-07-6
• 化学式: C₉H₆BrNS
• 分子量: 240.123
• InChiKey: AKNKWLQVFAYRRO-UHFFFAOYSA-N

物化性质

• 熔点：
  87 °C
• 沸点：
  301.7±27.0 °C(Predicted)
• 密度：
  1.563±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P322,P330,P332+P313,P337+P313,P340,P362,P363,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H312,H315,H319,H332,H335

SDS

Name:	2-(5-Bromo-2-thienyl)pyridine 97% Material Safety Data Sheet
Synonym:
CAS:	123784-07-6

Section 1 - Chemical Product MSDS Name:2-(5-Bromo-2-thienyl)pyridine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
123784-07-6	2-(5-Bromo-2-thienyl)pyridine	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 123784-07-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 86 - 88 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H6BrNS
Molecular Weight: 240.12

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acid chlorides, alcohols, amines.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide, hydrogen bromide, acrid smoke and fumes, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 123784-07-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(5-Bromo-2-thienyl)pyridine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 123784-07-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 123784-07-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 123784-07-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(5-溴-2-噻酚)吡啶 在 trans-benzyl(chloro)-bis(triphenylphosphine)palladium(II) 、 2-三丁基甲锡烷基噻吩 作用下， 以 甲苯 为溶剂， 反应 12.0h， 生成 5,5'-di(2-pyridyl)-2,2'-bithiophene
  参考文献：
  名称：

  Sosabowski, Michael H.; Powell, Paul, Journal of Chemical Research, Miniprint, 1997, # 1, p. 201 - 219

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴吡啶 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 sodium carbonate 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 生成 2-(5-溴-2-噻酚)吡啶
  参考文献：
  名称：

  β-链模拟：探索低聚噻吩基吡啶折叠体

  摘要：

  蛋白质-蛋白质相互作用 (PPI) 涉及许多细胞过程；因此，发现作为 PPI 调节剂的小分子已成为药物化学中的一个重要挑战。α-螺旋、β-转角或β-链的结构模拟物可以维持或恢复生物功能，并应具有生物活性。目前，最具挑战性的 PPI 类别是那些由 β-折叠相互作用介导的 PPI，它们与许多疾病有关。迄今为止，仅发表了少数 β 链模拟物。本研究根据低聚噻吩基吡啶基支架的 β 链模拟能力对它们进行了评估。在这项研究中，这些支架的理论环扭曲角预测已通过 X 射线衍射和具有 NMR 约束的分子动力学模拟得到验证。

  DOI：

  10.1002/ejoc.201600882

文献信息

• [EN] COMT INHIBITORS<br/>[FR] INHIBITEURS DE COMT
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014102233A1

  公开（公告）日：2014-07-03

  The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.

  本发明涉及式(I)的化合物，其中取代基如权利要求1所述，并且其药学上可接受的盐。这些化合物抑制酶儿茶酚-O-甲基转移酶(COMT)。这些化合物可用于治疗帕金森病、抑郁症、认知障碍和运动症状、抗抑郁症、认知障碍、情绪和精神分裂症的消极症状。
• [EN] 6-11 BICYCLIC KETOLIDE DERIVATIVES<br/>[FR] DERIVES DE CETOLIDE 6-11 BICYCLIQUES
  申请人：ENANTA PHARM INC

  公开号：WO2003097659A1

  公开（公告）日：2003-11-27

  The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了以下式(I)的化合物，或其药学上可接受的盐、酯或前药：具有抗菌性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗生素治疗的受试者使用。该发明还涉及通过给受试者使用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• [EN] 6-11 BICYCLIC KETOLIDE DERIVATIVES<br/>[FR] DERIVES KETOLIDES BICYCLIQUES 6-11
  申请人：ENANTA PHARM INC

  公开号：WO2005061525A1

  公开（公告）日：2005-07-07

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了具有以下结构的化合物，或其药学上可接受的盐、酯或前药：(I)，这些化合物具有抗菌性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗生素治疗的受试者进行治疗。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• [EN] 6-11 BICYCLIC KETOLIDE DRIVATIVES<br/>[FR] DERIVES DE KETOLIDE 6-11 BICYCLIQUES
  申请人：ENANTA PHARM INC

  公开号：WO2005061526A1

  公开（公告）日：2005-07-07

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formule (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了具有以下结构的化合物I，或其药学上可接受的盐、酯或前药：Formule (I)，其具有抗菌性能。本发明还涉及包括上述化合物的药物组合物，用于给需要抗生素治疗的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• Chromanes and their pharmaceutical compositions and methods
  申请人：Hoffmann-La Roche Inc.

  公开号：US05015661A1

  公开（公告）日：1991-05-14

  Racemic Compounds of the formula ##STR1## A is --C.tbd.C--R.sub.6, --CH.sub.2 --CH.sub.2 --R.sub.7 or ##STR2## R.sub.1 is hydrogen or lower alkanoyl, R.sub.2, R.sub.3, and R.sub.4 independently are hydrogen or lower alkyl, R.sub.5 is lower alkyl, R.sub.6 is a heteroaromatic radical or an aromatic radical selected from phenyl, naphthyl or phenanthryl, which aromatic radical may optionally be substituted by one or more substituents selected from chlorine, fluorine, lower alkyl, lower alkoxy, phenyl lower alkoxy, lower alkanoyl, lower alkanoyloxy, hydroxy-lower alkyl, carboxy, lower alkoxycarbonyl, hydroxyimino lower alkyl, amino, amino lower alkyl, mono- or di-lower alkylamino, mono- or di-lower alkylamino-lower alkyl, lower alkanoylamino, aminocarbonyl, lower alkylaminocarbonyl, lower dialkylaminocarbonyl, trifluoroacetylamino, trifluoromethyl, hydroxy, pyridyl, or on adjacent carbons can be ##STR3## wherein R' is hydrogen, lower alkanoyl, trifluoroacetyl and R" hydrogen or lower alkyl, R.sub.7 is a heteroaromatic radical or an aromatic radical selected from phenyl, naphthyl or phenanthryl, which aromatic radical may optionally be substituted by one or more substituents selected from chlorine, fluorine, lower alkyl, lower alkoxy, phenyl-lower alkoxy of 2-7 carbon atoms, lower alkanoyl, lower alkanoyloxy, hydroxy-lower alkyl, carboxy, lower alkoxycarbonyl, amino, amino-lower alkyl, mono- or di-lower alkylamino, mono- or di-lower alkylamino-lower alkyl, lower alkanoylamino, aminocarbonyl, lower alkylaminocarbonyl, lower dialkylaminocarbonyl, trifluoroacetylamino, trifluoromethyl, hydroxy or pyridyl, or on adjacent carbons can be ##STR4## wherein R' is hydrogen, lower alkanoyl, trifluoroacetyl and R" hydrogen or lower alkyl, R.sub.8, R.sub.9, R.sub.10, independently, are hydrogen, hydroxy, lower alkyl, lower alkoxy, hydroxy lower alkyl, fluorine, chlorine or lower alkanoyl provided that no more than one of R.sub.8, R.sub.9, and R.sub.10 is hydroxy, lower alkoxy, lower hydroxyalkyl, fluorine, chlorine or lower alkanoyl, and Y is CH or N, and their enantiomer and salts thereof are described. The compounds of formula I exhibit activity as inhibitors of 5-lipoxygenase and inhibit lipid peroxidation. They are, therefore, useful in the treatment of diseases caused or aggravated by excess oxidative metabolism of arachidonic acid via the 5-lipoxygenase pathway and in the treatment of inflammation, arthritis, allergies, asthma and psoriasis. The compounds of formula I can also be used to prevent peroxidation of lipids and thus protect lipid membranes from oxidative stress.

  公式为##STR1##的消旋化合物。其中A为--C.tbd.C--R.sub.6，--CH.sub.2 --CH.sub.2 --R.sub.7或##STR2##，R.sub.1为氢或较低的烷酰基，R.sub.2、R.sub.3和R.sub.4独立地为氢或较低的烷基，R.sub.5为较低的烷基，R.sub.6为异芳基或苯基，萘基或苯并芘基中选择的芳基，该芳基可以选择性地被氯、氟、较低烷基、较低烷氧基、苯基较低烷氧基、较低烷酰基、较低烷酰氧基、羟基较低烷基、羧基、较低烷氧羰基、羟基亚胺较低烷基、氨基、氨基较低烷基、单烷基氨基或二烷基氨基、单烷基氨基或二烷基氨基较低烷基、较低烷酰胺基、氨基羰基、较低烷基氨基羰基、较低二烷基氨基羰基、三氟乙酰氨基、三氟甲基、羟基、吡啶基或相邻碳上的可以是##STR3##，其中R'为氢、较低烷酰基、三氟乙酰基，R"为氢或较低烷基，R.sub.7为异芳基或苯基，选择自苯基、萘基或苯并芘基的芳基，该芳基可以选择性地被氯、氟、较低烷基、较低烷氧基、苯基较低烷氧基（碳原子数为2-7）、较低烷酰基、较低烷酰氧基、羟基较低烷基、羧基、较低烷氧羰基、氨基、氨基较低烷基、单烷基氨基或二烷基氨基、单烷基氨基或二烷基氨基较低烷基、较低烷酰胺基、氨基羰基、较低烷基氨基羰基、较低二烷基氨基羰基、三氟乙酰氨基、三氟甲基、羟基或吡啶基，或相邻碳上的可以是##STR4##，其中R'为氢、较低烷酰基、三氟乙酰基，R"为氢或较低烷基，R.sub.8、R.sub.9、R.sub.10独立地为氢、羟基、较低烷基、较低烷氧基、羟基较低烷基、氟、氯或较低烷酰基，但R.sub.8、R.sub.9和R.sub.10中不超过一个为羟基、较低烷氧基、较低羟基烷基、氟、氯或较低烷酰基，Y为CH或N，描述了它们的对映体和盐。公式I的化合物表现出作为5-脂氧酶抑制剂的活性，并抑制脂质过氧化。因此，它们在治疗由于花生四烯酸通过5-脂氧酶途径的过度氧化代谢引起或加重的疾病以及治疗炎症、关节炎、过敏、哮喘和牛皮癣方面是有用的。公式I的化合物还可用于预防脂质过氧化，从而保护脂质膜免受氧化应激的影响。